Research location
Grodno
Belarus
Advertisement
Research activity in Grodno
BelarusCureCurrent currently publishes aggregate city-level research activity for this location: 30 trials and 32 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Grodno
30 linked trials · page 1 of 1A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic MelanomaNCT05732805 · 2022-08-02 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)NCT04497844 · 2020-09-23 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)NCT04338061 · 2020-07-02 · 1 site observation
TERMINATED
An Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisNCT04130997 · 2019-11-18 · 2 site observations
ACTIVE_NOT_RECRUITING
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®NCT04115488 · 2019-10-01 · 1 site observation
COMPLETED
Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03NCT04109391 · 2019-08-20 · 1 site observation
COMPLETED
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate CancerNCT03871816 · 2019-04-22 · 1 site observation
COMPLETED
Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast CancerNCT03556358 · 2018-06-28 · 1 site observation
COMPLETED
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MSNCT03290131 · 2018-01-28 · 1 site observation
COMPLETED
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple SclerosisNCT03232073 · 2017-07-05 · 1 site observation
COMPLETED
A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung CancerNCT02754882 · 2016-07-05 · 1 site observation
COMPLETED
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple SclerosisNCT02576717 · 2015-10-16 · 1 site observation
COMPLETED
Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple SclerosisNCT02425644 · 2015-06-04 · 1 site observation
COMPLETED
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)NCT02294058 · 2014-12-03 · 1 site observation
COMPLETED
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)NCT02115750 · 2014-05-01 · 1 site observation
COMPLETED
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge PatientsNCT02111564 · 2014-01-07 · 1 site observation
COMPLETED
Efficacy and Safety Study of Ozanimod in Relapsing Multiple SclerosisNCT02047734 · 2013-12-03 · 2 site observations
COMPLETED
Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast CancerNCT01901146 · 2013-04-29 · 1 site observation
COMPLETED
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)NCT01707992 · 2013-02-20 · 1 site observation
COMPLETED
A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer PatientsNCT01764022 · 2012-10-01 · 1 site observation
COMPLETED
A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung CancerNCT01763645 · 2012-10-01 · 1 site observation
COMPLETED
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)NCT01578785 · 2012-03-01 · 1 site observation
TERMINATED
Efficacy and Safety of GTR in Comparison to Copaxone®NCT01489254 · 2011-10-01 · 1 site observation
COMPLETED
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseNCT01313676 · 2011-01-25 · 1 site observation
COMPLETED
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin TreatmentNCT01125566 · 2010-06-22 · 1 site observation
COMPLETED
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast CancerNCT00915018 · 2009-08-21 · 1 site observation
COMPLETED
Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast CancerNCT01091168 · 2009-07-01 · 1 site observation
COMPLETED
Trial of Vinflunine Plus Capecitabine in Advanced Breast CancerNCT01095003 · 2009-05-01 · 1 site observation
COMPLETED
An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple SclerosisNCT00751881 · 2008-08-01 · 1 site observation
COMPLETED
Study of Picoplatin Efficacy After RelapseNCT00465491 · 2007-04-01 · 1 site observation
UNKNOWN
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.